FDA Clears biospace med’s Revolutionary Low Dose Xray Imager; Technology Provides a ‘Total Solution’ to Orthopedic Imaging

PARIS and ATLANTA, Oct. 9 /PRNewswire/ -- Biospace med today announced that it has received 510k clearance from the Food and Drug Administration (FDA) to market EOS, a new digital Xray imager in the United States for 2D imaging use. EOS 2D|3D technology is part of a total solution to orthopedic imaging allowing images to be obtained with a low dose of radiation and is capable of long length digital imaging, permitting full-body, uninterrupted digital imaging with a single scan. Information submitted to FDA in support of Biospace med’s marketing application demonstrated up to 10 times reduction in dose when compared with commercially available film systems -- without compromising image quality.

MORE ON THIS TOPIC